Comparative Pharmacology
Head-to-head clinical analysis: LETERMOVIR versus TRIFLURIDINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LETERMOVIR versus TRIFLURIDINE.
LETERMOVIR vs TRIFLURIDINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Letermovir is an antiviral agent that inhibits the human cytomegalovirus (CMV) terminase complex, specifically the pUL56 subunit, thereby preventing viral DNA processing and packaging.
Trifluridine is a thymidine analog that inhibits thymidylate synthase and incorporates into DNA, leading to DNA damage and cell death.
480 mg orally once daily (two 240 mg tablets).
Topical: Apply one drop to affected eye every 2 hours while awake (maximum 9 drops/day) until re-epithelialization, then one drop every 4 hours for 7 days. Ophthalmic solution 1%.
None Documented
None Documented
The terminal elimination half-life is approximately 12 hours (range 10–18 hours) in healthy subjects, allowing once-daily dosing.
Clinical Note
moderateTrifluridine + Digoxin
"Trifluridine may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateTrifluridine + Digitoxin
"Trifluridine may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateTrifluridine + Deslanoside
"Trifluridine may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateTrifluridine + Acetyldigitoxin
"Trifluridine may decrease the cardiotoxic activities of Acetyldigitoxin."
The terminal elimination half-life of trifluridine is approximately 12-18 hours. This prolonged half-life supports twice-daily dosing and provides sustained exposure for antiviral activity.
Letermovir is primarily eliminated via biliary/fecal excretion (approximately 93% of the dose recovered in feces, with <2% as unchanged drug) and renal excretion accounts for <7% (mostly as metabolites, <1% unchanged).
Renal excretion accounts for approximately 40-50% of the administered dose, primarily as the inactive metabolite 5-trifluorothymidine. Fecal excretion is minimal (<5%). The remainder is eliminated via metabolic degradation.
Category C
Category C
Antiviral
Antiviral